FF-10101 is primarily investigated for its potential in cancer therapy, specifically as an anti-tumor agent. It demonstrates strong inhibitory activity against tumor cell proliferation, particularly in models of solid tumors. The compound has shown efficacy in inducing apoptosis and suppressing tumor growth in preclinical studies, making it a candidate for development in oncology treatments. Its mechanism supports targeted action on cancerous cells with reduced impact on healthy tissues, which may lead to fewer side effects compared to conventional chemotherapy. Research is ongoing to evaluate its use in combination with other anti-cancer drugs and its potential in treating resistant tumor types.